Sandoz, a Novartis division, is a pioneer and a global leader in biosimilars. We invest in research and development to improve patient lives and liberate healthcare resources through increased access to high-quality, affordable biologics.
With eight marketed biosimilars across immunology, oncology and endocrinology, we also have a leading biosimilars pipeline with more than 24 molecules in various stages of development1.
Our biosimilars have been used in clinical practice for over 15 years, and are available across the globe with over 1,300 million patient-days of experience2.
